NO. 018 · METABOLIC
AMYLIN RECEPTOR AGONIST
Long-acting amylin analog · investigational
ALIASES
amylin-receptor-agonist, AM833, long-acting amylin analog
CLASS
Synthetic amylin analog · once-weekly dual amylin/calcitonin agonist
FORMULA
C₁₈₀H₂₈₀N₅₂O₅₄ (approx)
SEQUENCE
37-residue amylin analog with C20-fatty-acid albumin tether
HALF-LIFE
~7 days (once-weekly dosing)
ROUTES
Subcutaneous (Phase 2/3 clinical)
MECHANISM OF ACTION
Long-acting amylin analog. Activates amylin and calcitonin receptors to slow gastric emptying and modulate satiety signaling. Forms the the amylin receptor agonist-half of the CagriSema combination program with the long-acting GLP-1 agonist.
EVIDENCE GRADES
Lau 2021 Lancet · dose-dependent placebo-subtracted weight loss to ~10.8% at 26 weeks.
Frias 2023 Lancet · combination outperforms monotherapy components in T2D + obesity Phase 2; Phase 3 REDEFINE program ongoing.
SAFETY
Side effects
- GI: nausea, vomiting (titration-dependent)
- Injection-site reactions
- Hypoglycemia risk when combined with insulin
Drug interactions
- Insulin · additive hypoglycemia risk
Contraindications
- History of MTC or MEN2 (theoretical class effect)
REGULATORY STATUS
FDA · Not yet FDA-approved as of 2026-05. Phase 3 REDEFINE program ongoing for CagriSema combination.
WADA · Not currently listed on the WADA Prohibited List.
STORAGE
Lyophilized · -20 °C 24 months
Reconstituted · 2-8 °C, 28 days
PEER-REVIEWED EVIDENCE
- Lau DCW, et al.. Once-weekly the amylin receptor agonist for weight management in people with overweight and obesity. Lancet 2021. PMID 34247670. link →
- Frias JP, et al.. Efficacy and safety of co-administered once-weekly the amylin receptor agonist 2·4 mg with once-weekly the long-acting GLP-1 agonist 2·4 mg in type 2 diabetes. Lancet 2023. PMID 37364590. link →
FAQ · 7 QUESTIONS
▶ What is the amylin receptor agonist?
the amylin receptor agonist is a synthetic long-acting amylin analog developed by the originator pharma sponsor for once-weekly subcutaneous administration. Native amylin is co-secreted with insulin by pancreatic beta cells and promotes satiety, slowed gastric emptying, and reduced postprandial glucagon.
▶ How is the amylin receptor agonist different from pramlintide?
Pramlintide (Symlin) is the short-acting amylin analog FDA-approved 2005 for adjunctive use with insulin in type 1 and insulin-treated type 2 diabetes. the amylin receptor agonist is the long-acting analog with C20 fatty-acid albumin tether enabling once-weekly dosing for weight management.
▶ What is CagriSema?
CagriSema is the fixed-ratio combination of the amylin receptor agonist + the long-acting GLP-1 agonist developed by the originator pharma sponsor as a single weekly injection for obesity. Phase 2 trials reported greater weight loss than either monotherapy.
▶ Is the amylin receptor agonist FDA-approved?
Not yet as of 2026-05. The Phase 3 REDEFINE program for CagriSema in obesity is ongoing.
▶ How does the amylin receptor agonist work?
Dual agonism at the amylin receptor (a heterodimer of calcitonin receptor + RAMP1/2/3) and the calcitonin receptor in area postrema and arcuate nucleus, reducing food intake and promoting satiety. Mechanism complements GLP-1 receptor signaling.
▶ What's the dose in trials?
Phase 2 used subcutaneous 2.4 mg once weekly matching the the long-acting GLP-1 agonist dosing rhythm. This wiki does not recommend any human dose.
▶ Side effects?
GI side effects (nausea, vomiting) are titration-dependent. Class precaution for MTC/MEN2 from preclinical thyroid C-cell observations.
SIGNATURE MOVES
Slows gastric emptying. Amylin receptor activation.
Stacks with the long-acting GLP-1 agonist. REDEFINE Phase 3 program.
SOURCED FROM GIGACOMPOUNDS
Reference compounds documented on this page are available as research-grade material at GigaCompounds · ≥99% purity · per-batch Certificate of Analysis. For laboratory research use only. No human dose is recommended by this wiki.
▶ LAST UPDATED · 2026-05-19